This is the third program that s uccessfully combine s Entera’s oral peptide N- Tab ® platform with OPKO ’s advanced protein chemistry capabilities The c ompanies have...
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK ) announced today that management will be participating in the 44 th Annual J.P. Morgan Healthcare Conference, being held January...
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37 th Annual Healthcare Conference, being held December...
Company Reports $13.8M in Q3Â Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026Â
MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights...
Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29,...
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 ...
MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the...
BURLINGTON, N.C. and MIAMI , Sept. 15, 2025 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health,...